Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajsl1623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/CAplus enhanced with utility model patents from China
NEWS 6 JUL 16 CAplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/CAplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 12 AUG 13 CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15 AUG 27 USPATOLD now available on STN
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18 SEP 13 FORIS renamed to SOFIS
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 20 SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21 SEP 17 CAplus coverage extended to include traditional medicine patents
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24 OCT 19 BEILSTEIN updated with new compounds
NEWS 25 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 26 NOV 19 WPIX enhanced with XML display format
NEWS 27 NOV 30 ICSD reloaded with enhancements
NEWS 28 DEC 04 LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:36:23 ON 12 DEC 2007

=> b caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 12:36:36 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Dec 2007 VOL 147 ISS 25
FILE LAST UPDATED: 11 Dec 2007 (20071211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> b caplus, biosis
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.47	0.68

FILE 'CAPLUS' ENTERED AT 12:36:44 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'BIOSIS' ENTERED AT 12:36:44 ON 12 DEC 2007

=> s fenofibrate and voglibose
L1 9 FENOFIBRATE AND VOGLIBOSE

=> s l1 and py<=2005
L2 7 L1 AND PY<=2005

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3 7 DUP REM L2 (0 DUPLICATES REMOVED)

=> d l3 ibib abs 1-7

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1075524 CAPLUS
DOCUMENT NUMBER: 143:367288
TITLE: Preparation of 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders
INVENTOR(S): Heurich, Rainer
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 302 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005091857	A2	20051006	WO 2005-US5367	20050224 <--
WO 2005091857	A3	20061005		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-552971P P 20040312
OTHER SOURCE(S): MARPAT 143:367288
GI



I



II

AB The title compds. I and II [R1 = alkyl, alkenyl, alkynyl, aryl, etc.; R2 = NR15R16, S(O)0-2R17, OR17 (wherein R15 = H, alkyl, cycloalkyl, etc.; R16 = alkyl, alkenyl, aryl, etc.; R17 = alkyl, alkenyl, aryl, etc.); R3 = aryl, heteroaryl, cycloalkyl, etc.; R4 = O, S, OR21 (R21 = H, alkyl, cycloalkyl, etc.); R5-R8 = cycloalkyl, aryl, heteroaryl, etc.], useful for the treatment of diabetes and related disorders (no specific biol. data given), were prepared Thus, reacting 7-chloro-5-methyl-1-phenyl-2-phenylamino-1H-[1,8]naphthyridin-4-one with morpholine in dioxane afforded 92% 5-methyl-7-(morpholin-4-yl)-1-phenyl-2-phenylamino-1H-[1,8]naphthyridin-4-one. The pharmaceutical comprns. containing the compds. I alone or in combination with other therapeutic agents are disclosed.

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:823553 CAPLUS
DOCUMENT NUMBER: 143:199940
TITLE: Combination drug containing antihyperlipidemics and α-glucosidase inhibitors
INVENTOR(S): Kanazawa, Hashime; Ishitani, Kouki; Sudo, Katsuichi; Tanimori, Naoto
PATENT ASSIGNEE(S): Grelan Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074909	A1	20050818	WO 2005-JP1801	20050208 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2555316	A1	20050818	CA 2005-2555316	20050208 <--
EP 1714648	A1	20061025	EP 2005-709853	20050208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 2007197602	A1	20070823	US 2006-588725	20060808
PRIORITY APPLN. INFO.:			JP 2004-32329 A	20040209
			WO 2005-JP1801 W	20050208

AB Disclosed is a drug which contains a combination of the active ingredients comprising at least one remedy for hyperlipemia selected from the group consisting of fibrate compds. (fenofibrate, bezafibrate, salts thereof, etc.) and HMG-CoA reductase inhibitors (statin compds. such as pravastatin, atorvastatin, salts thereof, etc.) with an α-glucosidase inhibitor (voglibose, acarbose, etc.). The content of the α-glucosidase inhibitor may be from 0.001 to 50 parts by weight per 100 parts by weight of the remedy for hyperlipemia. Thus, it is possible to provide a drug having excellent effects of preventing and/or treating metabolic syndrome, hyperlipemia, diabetes, diabetic complications, etc. with little side effect. For example, the effect of combination of fenofibrate and voglibose was examined in streptozotocin-induced diabetic rats. Also, a tablet containing fenofibrate 100, voglibose 0.2, lactose 69.2, fine crystalline cellulose 29.6, magnesium stearate 1 mg was formulated.
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:729537 CAPLUS
DOCUMENT NUMBER: 143:211920
TITLE: Preparation of diacylglycerol acyltransferase (DGAT1) inhibitors as anorectics.
INVENTOR(S): Ogawa, Nobuya; Okuma, Chihiro; Furukawa, Noboru
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan; Amgen Sf, LLC
SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072740	A2	20050811	WO 2005-JP1643	20050128 <--
WO 2005072740	A3	20051027		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005209115	A1	20050811	AU 2005-209115	20050128 <--
CA 2554455	A1	20050811	CA 2005-2554455	20050128 <--
EP 1718309	A2	20061108	EP 2005-704403	20050128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1913899	A	20070214	CN 2005-80003524	20050128
JP 2007519605	T	20070719	JP 2006-524132	20050128
US 2007027093	A1	20070201	US 2006-495095	20060728
IN 2006CN03150	A	20070608	IN 2006-CN3150	20060830

PRIORITY APPLN. INFO.:			
	JP 2004-24812	A	20040130
	US 2004-598037P	P	20040802
	WO 2005-JP1643	W	20050128

OTHER SOURCE(S): CASREACT 143:211920; MARPAT 143:211920
GI



I

AB Claimed are anorectics comprising as active ingredients compds. having DGAT inhibitory activity (DGAT1 inhibitory activity) or a prodrugs or a pharmaceutically acceptable salts thereof. Thus, title compound (I) (preparation given) at 10 mg/kg orally in rats gave a 30% reduction in food consumption after 8 h.

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:120729 CAPLUS
DOCUMENT NUMBER: 142:219276
TITLE: Preparation of 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the RUP25 nicotinic

acid receptor for the treatment of dyslipidemia and related diseases

INVENTOR(S): Semple, Graeme; Gharbaoui, Tawfik; Shin, Young-Jun; Decaire, Marc; Averbuj, Claudia; Skinner, Philip J.

PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011677	A1	20050210	WO 2004-US18389	20040610 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004260636	A1	20050210	AU 2004-260636	20040610 <--
CA 2528834	A1	20050210	CA 2004-2528834	20040610 <--
EP 1633351	A1	20060315	EP 2004-776418	20040610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2007032537	A1	20070208	US 2006-560332	20060908

PRIORITY APPLN. INFO.: US 2003-478664P P 20030613
WO 2004-US18389 W 20040610

OTHER SOURCE(S): MARPAT 142:219276

GI



I

AB Title compds. [I; W, Y = (substituted) alkylene, alkenylene, alkynylene; X = NR3CO, NR3SO2, NR3, CO, CH(OH), C(NH), O, S, SO, SO2, etc.; R3, R4 = H, (substituted) alkyl, Ph, heteroaryl; Z = H, halo, (substituted) Ph, heteroaryl; R1 = H, OH, halo, alkyl, haloalkyl; R2 = H, alkyl; m, n = 0, 1; with provisos], were prepared Thus, 5-methylthiomethyl-2H-pyrazole-3-carboxylic acid (preparation outlined) showed hRUP25 agonist activity with EC50 = 4.3 μM.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:14212 CAPLUS

DOCUMENT NUMBER: 142:107414

TITLE: Compositions comprising balaglitazone and further antidiabetic compounds
INVENTOR(S): Wassermann, Karsten; Wulff, Erik Max
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000299	A1	20050106	WO 2004-DK448	20040624 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004250994	A1	20050106	AU 2004-250994	20040624 <--
CA 2530228	A1	20050106	CA 2004-2530228	20040624 <--
EP 1638554	A1	20060329	EP 2004-738945	20040624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004012009	A	20060815	BR 2004-12009	20040624
CN 1826112	A	20060830	CN 2004-80020764	20040624
JP 2007506649	T	20070322	JP 2006-515731	20040624
US 2007010423	A1	20070111	US 2005-561639	20051220

PRIORITY APPLN. INFO.:			
DK 2003-973	A	20030627	
US 2003-483196P	P	20030627	
WO 2004-DK448	W	20040624	

AB Methods for the treatment of type 2 diabetes and related conditions comprising the administration of balaglitazone in combination with one or more other antidiabetic compound is provided together with combinations useful in said treatment.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:878382 CAPLUS
DOCUMENT NUMBER: 141:350161
TITLE: Preparation of azole compounds as PTP1B inhibitors
INVENTOR(S): Ikemoto, Tomoyuki; Tanaka, Masahiro; Yuno, Takeo; Sakamoto, Johei; Nakanishi, Hiroyuki; Nakagawa, Yuichi; Ohta, Takeshi; Sakata, Shohei; Morinaga, Hisayo
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 542 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004089918 A1 20041021 WO 2004-JP5119 20040409 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2004228565 A1 20041021 AU 2004-228565 20040409 <--
CA 2521830 A1 20041021 CA 2004-2521830 20040409 <--
EP 1553091 A1 20050713 EP 2004-726765 20040409 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
BR 2004009136 A 20060425 BR 2004-9136 20040409
CN 1780823 A 20060531 CN 2004-80009487 20040409
JP 3819415 B2 20060906 JP 2005-505323 20040409
JP 2005272476 A 20051006 JP 2005-133755 20050428 <--
US 2006122181 A1 20060608 US 2005-176846 20050707
NO 2005005246 A 20051221 NO 2005-5246 20051108 <--
IN 2005CN02927 A 20070608 IN 2005-CN2927 20051109
PRIORITY APPLN. INFO.: JP 2003-105267 A 20030409
JP 2003-157590 A 20030603
JP 2005-505323 A3 20040409
WO 2004-JP5119 W 20040409
OTHER SOURCE(S): MARPAT 141:350161
GI





AB Title compds. I [V = N, CH; W = S, O; m = 0-2; R1, R2 = H, alkyl; X = NR4, etc.; R4 = H, alkyl; n = 0-4; p = 0, 1; L = CR20R21, etc.; R20 = H, alkyl,

etc.; R21 = H, alkyl, etc.; R = CO2R19, etc.; R19 = H, alkyl; B = aryl, heteroaryl; R3 = H, halo, etc.; Y = O, etc.; s = 0, 1; A = (un)substituted alkylene with cycloalkyl; Z = cycloalkyl, etc.] were prepared For example, O-alkylation of 5-hydroxynicotinic acid Me ester with compound II [Q = Cl], e.g., prepared from 4-bromoacetylbenzoic acid in 5 steps, followed by saponification afforded compound II [3-carboxypyridin-5-yloxy] in 44.1% overall yield. In PTP1B (protein tyrosine phosphatase 1B) inhibition assays, the IC50 value of compound II [Q = 3-carboxypyridin-5-yloxy] was 0.28 μM. Compds. I are claimed useful for the treatment of obesity, diabetes, etc. Formulations are given.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:333698 CAPLUS
DOCUMENT NUMBER: 140:357333
TITLE: Preparation of aroylhydroxypyrazoles for treatment of metabolic disorders
INVENTOR(S): Semple, Graeme; Shin, Young Jun
PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033431	A2	20040422	WO 2003-US31509	20031002 <--
WO 2004033431	A3	20040729		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003282679	A1	20040504	AU 2003-282679	20031002 <--

PRIORITY APPLN. INFO.: US 2002-416193P P 20021004
US 2002-417120P P 20021007
WO 2003-US31509 W 20031002

OTHER SOURCE(S): MARPAT 140:357333
GI



I

AB Title compds. [I; R1 = alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, benzyl, optionally substituted with ≥1 halo, OH, cyano, NO2,

haloalkyl, amino, aminoalkyl, aminodialkyl, alkyl, cycloalkyl, alkoxy, phenoxy, alkenyl, alkynyl, haloalkoxy, carboxy, carboalkoxy, alkylcarboxamido, arylcarboxamido, heteroarylcarboxamido, heterocyclic carboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, haloalkylthio, haloalkylsulfinyl, haloalklcylsulfonyl, alkylureyl, arylureyl; R2 = H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, PhCH2, Ph, heteroaryl, optionally substituted with ≥1 halo, OH, cyano, nitro, haloalkyl, amino, aminoalkyl, aminodialkyl, alkyl, cycloalkyl, alkoxy, phenoxy, alkenyl, alkynyl, haloalkoxy, carboxy, carboalkoxy, alkylcarboxamido, arylcarboxamido, heteroarylcarboxamido, heterocyclic carboxamido, alkylthio, alkylsulfmyl, alkylsulfonyl, haloalkylthio, haloalkylsulfinyl, haloalkylsulfonyl, alkylureyl or arylureyl groups; Ar = (substituted) pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl], were prepared for the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like (no data). Thus, nicotinyl chloride, 2-methyl-5-propyl-2,4-dihydropyrazol-3-one, and Ca(OH)2 were heated at 90° in dioxane for 2 h. to give (5-hydroxy-1-methyl-3-propyl-1H-pyrazol-4-yl)pyridin-3-ylmethanone. I may be used in combination with other active agents such α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme inhibitors, and insulin secretion enhancers.

```
=> d his

     (FILE 'HOME' ENTERED AT 12:36:23 ON 12 DEC 2007)

     FILE 'CAPLUS' ENTERED AT 12:36:36 ON 12 DEC 2007

     FILE 'CAPLUS, BIOSIS' ENTERED AT 12:36:44 ON 12 DEC 2007
L1             9 S FENOFIBRATE AND VOGLIBOSE
L2             7 S L1 AND PY<=2005
L3             7 DUP REM L2 (0 DUPLICATES REMOVED)

=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    27.20      27.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -5.46      -5.46

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:38:09 ON 12 DEC 2007
```